Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells-Reference-Cited by-同舟云学术

Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells

Published:2014-09 Issue:8 Volume:25 Page:868-877
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Matsunaga Toshiyuki,Yamaguchi Ayano,Morikawa Yoshifumi,Kezuka Chihiro,Takazawa Hiroaki,Endo Satoshi,El-Kabbani Ossama,Tajima Kazuo,Ikari Akira,Hara Akira

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference34 articles.

1. Drug therapy for acute myeloid leukemia.;Tallman;Blood,2005

2. Signaling pathways activated by daunorubicin.;Laurent;Blood,2001

3. Cytoprotective agents for anthracyclines.;Dorr;Semin Oncol,1996

4. Treatment of elderly acute myeloid leukemia patients.;Motyckova;Curr Treat Options Oncol,2011

5. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds.;Matsunaga;Drug Metab Pharmacokinet,2006

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis;PLOS ONE;2024-01-16

2. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer;Chemico-Biological Interactions;2024-01

3. IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer;Journal of Biological Chemistry;2023-06

4. Analysis of the mechanism of aldo-keto reductase dependent cis-platin resistance in HepG2 cells based on transcriptomic and NADH metabolic state;BIOCELL;2023

5. AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming;Translational Oncology;2022-06